Has Laura Butz, MD received payments from drug or device companies?

Yes. Drug and device makers reported $44,209 in general payments to Laura Butz, MD across 932 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Laura Butz, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Laura Butz, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Laura Butz, MD

Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1538452404

Payments from drug & device makers

$44,209in general payments, 2019–2025

Across 932 payments — averaging $47.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Xeris Pharmaceuticals, Inc.$29K
Amgen$1K
Novo Nordisk$1K
Lilly USA, LLC$1K
Insulet Corporation$913
Tandem Diabetes Care, Inc.$902
plus $9K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Xeris Pharmaceuticals, Inc.	129	$29,347
Amgen(2 entities)	82	$1,268
Novo Nordisk	87	$1,224
Lilly USA, LLC	72	$1,172
Insulet Corporation	45	$913
Tandem Diabetes Care, Inc.	14	$902
Dexcom, Inc.	35	$818
Abbott	41	$633
Bayer	39	$627
Sanofi-aventis U.S. LLC	33	$528
AstraZeneca(2 entities)	25	$489
Amneal Pharmaceuticals LLC	21	$394
AbbVie	18	$372
Corcept Therapeutics	19	$370
Boehringer Ingelheim	21	$356
Novartis	20	$345
Radius Health, Inc.	20	$338
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	19	$313
BETA Bionics, Inc.	14	$301
Antares Pharma, Inc.	16	$294
Pfizer	15	$255
Amarin Pharma, Inc.	11	$211
Sequel Med Tech, LLC	4	$198
Johnson & Johnson	14	$174
IBSA Pharma Inc.	10	$171
Cequr Corporation	3	$161
Neurocrine Biosciences, Inc.	5	$158
Lifescan, Inc.	8	$141
Endo USA, Inc.	5	$118
Medtronic(2 entities)	6	$114
Endo Pharmaceuticals Inc.	6	$99
Merck	7	$96
Almatica Pharma LLC	4	$95
Ultragenyx Pharmaceutical Inc.	4	$88
Ipsen Biopharmaceuticals, Inc	2	$74
Kyowa Kirin, Inc.	4	$73
Kowa Pharmaceuticals America, Inc.	3	$72
Ascendis Pharma Endocrinology Inc	3	$65
Mannkind Corporation	5	$65
Zealand Pharma US, Inc.	4	$63
Amryt Pharma Holdings Ltd	4	$59
Sandoz	2	$55
Regeneron Healthcare Solutions, Inc.	3	$52
Shire North American Group Inc	4	$51
Esperion Therapeutics, Inc.	3	$50
Chiesi USA, Inc.	2	$42
Madrigal Pharmaceuticals	1	$41
Rhythm Pharmaceuticals, Inc.	2	$40
Recordati_rare_diseases_inc.	2	$39
Amphastar Pharmaceuticals, Inc.	2	$37
Halozyme Inc	2	$36
Ascensia Diabetes Care US Inc.	2	$33
Avvisto Therapeutics, LLC	2	$32
Tolmar, Inc.	2	$29
BD	1	$26
Companion Medical, Inc.	1	$23
Renalytix AI, Inc.	1	$20
OPKO Pharmaceuticals, LLC	1	$17
Eisai Inc.	1	$17
RGH Enterprises LLC	1	$16

How this compares

$44,209 in reported general payments places this provider in the 80th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio →

Medicare billing

Part B allowed, 2024

$74,748

Medicare patients

423

Services billed

1,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Columbus

Elena ChristofidesColumbus$3.5M
Steven IngColumbus$1.9M
Kathleen DunganColumbus$1.4M
Kyaw SoeColumbus$1.3M
Samuel AndersonColumbus$556K
Kathleen WyneColumbus$510K
Luma GhalibColumbus$180K
Ravi DhawaleColumbus$175K
Lawrence KirschnerColumbus$142K
Laura RyanColumbus$126K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →